The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population
NCT ID: NCT05090631
Last Updated: 2023-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
600 participants
OBSERVATIONAL
2021-10-23
2023-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis
NCT00515047
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
NCT03304470
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
NCT03654755
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
NCT04212169
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group:
Patients with atopic dermatitis
DNA analysis
GWAS
Control group
Patients without atopic dermatitis
DNA analysis
GWAS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
GWAS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The age of the patients is from 18 to 45+ years;
* Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.
* Persons who are able and willing to provide written informed consent;
* Persons capable and willing to comply with the research protocol;
Exclusion Criteria
* Patients with severe concomitant systemic diseases, including cardiovascular, respiratory, hepatic and renal failure
* Patients with severe infectious processes (sepsis, abscess, hepatitis B and C, HIV)
* Persons with mental illness.
* Persons taking corticosteroid drugs, immunosuppressants within the last month;
* Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Pregnant or lactating women;
* Tuberculosis of any localization in the active phase and in history;
* Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
* Severe and decompensated course of endocrine diseases;
* Autoimmune diseases;
* Systemic diseases;
* Oncological diseases;
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asfendiyarov Kazakh National Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ildar Fakhradiyev
Head of the Laboratory of Experimental Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gulya Sarybaeva, PhD
Role: PRINCIPAL_INVESTIGATOR
Asfendiyarov Kazakh National Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kazakhstan
Almaty, , Kazakhstan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1196
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.